SRPT Q2 2025 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$611M+68.4% YoY

Gross Profit

$459M75.0% margin

Operating Income

$116M18.9% margin

Net Income

$197M32.2% margin

EPS (Diluted)

$1.89

QoQ Revenue Growth

-18.0%

Cash Flow

Operating Cash Flow

$261M

Free Cash Flow

$229M

Stock-Based Comp.

$37M

Balance Sheet

Total Assets

$3.7B

Total Liabilities

$2.3B

Stockholders' Equity

$1.4B

Cash & Equivalents

$511M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$611M	$363M	+68.4%
Gross Profit	$459M	$318M	+44.0%
Operating Income	$116M	-$701,000	+16587.4%
Net Income	$197M	$6M	+2947.9%

Geographic Segments

UNITED STATES

$282M91%

Rest of World

$28M9%